- Home
- LSPD vs EYPT Comparison
LSPD vs EYPT Comparison
Compare LSPD & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSPD | EYPT |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LSPD | EYPT |
|---|---|---|
| Price | $9.42 | $17.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 4 |
| Target Price | $13.40 | ★ $28.75 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $15.43 | N/A |
| Revenue Next Year | $11.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.34 | $3.91 |
| 52 Week High | $14.34 | $19.11 |
Technical Indicators
Market Signals| Indicator | LSPD | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 67.39 |
| Support Level | $8.41 | $11.88 |
| Resistance Level | $12.55 | $19.06 |
| Average True Range (ATR) | 0.38 | 1.20 |
| MACD | 0.08 | 0.59 |
| Stochastic Oscillator | 82.73 | 98.04 |
Price Performance
Historical ComparisonAbout LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.